Rome IV Functional Constipation Clinical Trial
Official title:
MIcrobiome Analysis of Chronically Constipated Versus Non-constipated Populations for Detection of Novel Molecular Entities With Therapeutic Potential
NCT number | NCT04106232 |
Other study ID # | HGP-0008 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | January 24, 2020 |
Est. completion date | March 6, 2023 |
Verified date | November 2022 |
Source | HyGIeaCare, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study intends to evaluate the microbiome of chronically constipated patients as compared to those with a non-constipated gastrointestinal system.
Status | Completed |
Enrollment | 30 |
Est. completion date | March 6, 2023 |
Est. primary completion date | March 6, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Patient's age is between 18 and 80 years old. 2. For the healthy population - Indication for age-appropriate colorectal cancer screening colonoscopy 3. Adequate capacity to consent to study 4. Patient does not have any known health issues, except for chronic constipation for the "chronic constipation" population. 5. Patient has not taken antibiotics within the last three (3) months. 6. For chronically constipated patients - >3 months of symptomatic constipation with first onset of constipation more than 6 months ago. For chronically constipated patients - Diagnosis of functional constipation by Modified Rome IV Diagnostic Criteria. Exclusion Criteria: 1. Patient has functional bowel disorders characterized by alternating bowel habits (diarrhea/constipation). 2. Patient has any other condition that, in the opinion of the investigator, may adversely affect the compliance or safety of the patient or would limit the patient's ability to complete the study. 3. Current, or recent (within three months) antibiotic usage Patient has any of the contraindications listed below: 4. Cardiac: Congestive heart failure (NYHA class III or IV or EF <50%) 5. GI: Intestinal perforation, carcinoma of the rectum, fissures or fistula, severe hemorrhoids, abdominal hernia, recent colon or rectal surgery, or abdominal surgery 6. GU: Renal insufficiency (CC < 60 ml/min/173m2), cirrhosis with ascites 7. Abdominal surgery within the last 6 months 8. Pregnancy |
Country | Name | City | State |
---|---|---|---|
United States | Hygieacare - Norwood | Cincinnati | Ohio |
United States | Hygieacare Center - Flowood | Flowood | Mississippi |
United States | HyGIeaCare Center | Norfolk | Virginia |
Lead Sponsor | Collaborator |
---|---|
HyGIeaCare, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Identify the presence of microbial substances within stool samples taken from different locations along the colon | Finding novel molecular entities with therapeutic potential for chronic constipation using the unique HyGIeaCare approach for constipation relief and collection of fecal material for analysis. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04532879 -
HygiRelief Procedure and HygiSample Evaluation for Functional Constipation
|
N/A |